244 related articles for article (PubMed ID: 1778316)
1. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Novotny P; Chubb AP; Cownley K; Charles IG
Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
[TBL] [Abstract][Full Text] [Related]
2. Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine.
Novotny P; Chubb AP; Cownley K; Charles IG
J Infect Dis; 1991 Jul; 164(1):114-22. PubMed ID: 2056199
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
Winsnes R; Lønnes T; Møgster B; Berdal BP
Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
[TBL] [Abstract][Full Text] [Related]
4. Protection against intranasal infection of mice with Bordetella pertussis.
Robinson A; Ashworth LA; Baskerville A; Irons LI
Dev Biol Stand; 1985; 61():165-72. PubMed ID: 2872102
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
6. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
7. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
8. Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines.
Tiru M; Jäätmaa E; Gillenius P; Askelöf P
Dev Biol Stand; 1985; 61():469-75. PubMed ID: 2872128
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
10. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
11. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional properties of a 69-kilodalton outer membrane protein of Bordetella pertussis.
Brennan MJ; Li ZM; Shahin RD; Burns DL; Nguyen NY; Liu TY; Gray MC; Hewlett EL; Manclark CR
Tokai J Exp Clin Med; 1988; 13 Suppl():211-5. PubMed ID: 2908522
[TBL] [Abstract][Full Text] [Related]
13. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
14. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.
Marr N; Oliver DC; Laurent V; Poolman J; Denoël P; Fernandez RC
Vaccine; 2008 Aug; 26(34):4306-11. PubMed ID: 18582518
[TBL] [Abstract][Full Text] [Related]
15. Effect of heptakis (2,6-0-dimethyl)beta-cyclodextrin on cell growth and the production of pertussis toxin and filamentous hemagglutinin in Bordetella pertussis.
Suzuki Y; Imaizumi A; Ginnaga A; Sato H; Sato Y
Dev Biol Stand; 1985; 61():89-92. PubMed ID: 2872134
[TBL] [Abstract][Full Text] [Related]
16. Aerosol infection test for evaluation of pertussis vaccine.
Syukuda Y; Watanabe H; Suehara A; Fujii S; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1988; 13 Suppl():71-7. PubMed ID: 2908529
[TBL] [Abstract][Full Text] [Related]
17. Potency assay and characterization of lymphocytosis promoting factor in whole cell and acellular pertussis vaccines.
Tiru M; Falk A; Brym-Grynblat B; Pettersson IM
Dev Biol Stand; 1991; 73():157-65. PubMed ID: 1778309
[TBL] [Abstract][Full Text] [Related]
18. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
19. Filamentous hemagglutinin of Bordetella pertussis. A bacterial adhesin formed as a 50-nm monomeric rigid rod based on a 19-residue repeat motif rich in beta strands and turns.
Makhov AM; Hannah JH; Brennan MJ; Trus BL; Kocsis E; Conway JF; Wingfield PT; Simon MN; Steven AC
J Mol Biol; 1994 Aug; 241(1):110-24. PubMed ID: 7519681
[TBL] [Abstract][Full Text] [Related]
20. [Determination of the immune potency of lymphocyte-promoting factor (LPF) and filamentous hemagglutinin (FHA) molecules by intranasal challenge in mice].
Ozcengiz E; Günalp A
Mikrobiyol Bul; 1991 Apr; 25(2):131-7. PubMed ID: 1745145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
